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CONSENSUS STATEMENT
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Christopher M. Jones1,2,3, Ganesh Radhakrishna4, Katharine Aitken5,6, John Bridgewater 7, Pippa Corrie 8, Martin Eatock9,
Rebecca Goody2,3, Paula Ghaneh10, James Good11, Derek Grose12, Daniel Holyoake13, Arabella Hunt5,6, Nigel B. Jamieson14,
Daniel H. Palmer15,16, Zahir Soonawalla17, Juan W. Valle 4,18, Maria A. Hawkins19 and Somnath Mukherjee 20
The coronavirus disease 2019 (COVID-19) pandemic epicentre has moved to the USA and Europe, where it is placing
unprecedented demands on healthcare resources and staff availability. These service constraints, coupled with concerns relating to
an increased incidence and severity of COVID-19 among patients with cancer, should lead to re-consideration of the risk–benefit
balance for standard treatment pathways. This is of particular importance to pancreatic cancer, given that standard diagnostic
modalities such as endoscopy may be restricted, and that disease biology precludes significant delays in treatment. In light of this,
we sought consensus from UK clinicians with an interest in pancreatic cancer for management approaches that would minimise
patient risk and accommodate for healthcare service restrictions. The outcomes are described here and include recommendations
for treatment prioritisation, strategies to bridge to later surgical resection in resectable disease and factors that modify the
risk–benefit balance for treatment in the resectable through to the metastatic settings. Priority is given to strategies that limit
hospital visits, including through the use of hypofractionated precision radiotherapy and chemoradiotherapy treatment
approaches.
British Journal of Cancer https://doi.org/10.1038/s41416-020-0980-x
BACKGROUND
Following the first reports of infection with severe acute
respiratory syndrome coronavirus 2 during December 2019 in
Wuhan, China, cases of coronavirus disease 2019 (COVID-19) have
dramatically increased across the world.1 With its epicentre now in
Europe and the USA, the COVID-19 pandemic is placing
unprecedented demands on healthcare resources across a
number of countries. This includes the United Kingdom (UK),
where increasing numbers of patients critically unwell from
COVID-19 have in some areas severely diminished bed availability
within high-dependency and intensive care units, reducing
surgical capacity as a consequence. A reduction in the numbers
of frontline healthcare workers through infection and self-isolation
is also increasing service pressures.
Adding further challenge to standard cancer treatment path-
ways, a majority of patients with cancer are immunosuppressed
and may be more likely to contract COVID-19.2–6 Given that
hospitals act as a reservoir for infection, this risk is amplified by
multiple hospital attendances for cancer diagnosis, treatment and
follow-up. A cancer diagnosis and recent anticancer treatment
may additionally be linked to greater severity of COVID-19.2–6 As
such, the risk–benefit balance is likely to have changed for a
number of cancer treatments, although it should be noted that
evidence of the magnitude of risk conferred by COVID-19 for
patients with cancer, and for those receiving anticancer therapies,
remains uncertain.7 Adding further complexity, cancer services
must now forward plan for possible recurrent peaks in COVID-19
incidence while managing the lasting consequences of the first
outbreak. This includes both a backlog of cases resulting from the
clear pivot of the National Health Service (NHS) towards a focus on
COVID-19 treatment and, in some areas, continuing to grapple
with a prolonged plateau in first peak COVID-19 incidence.
In light of this, we convened an expert group of UK clinicians
with expertise in pancreatic cancer. The panel identified areas in
which resource limitations or the potential for SARS-CoV-2
infection would potentially increase the risks of, or limit access
to, current standard treatments for pancreatic cancer. This included
a review of guidance relating to COVID-19 published by NHS
England and other relevant UK professional bodies. Alternative
management strategies for these scenarios were sought via
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literature review and through input from panel members.
Identified options were virtually reviewed by the panel and used
to formulate an initial guidance document. This subsequently
received iterative input from the panel until consensus was
reached, with a focus throughout on management approaches
that would minimise risk to the patient and accommodate for
healthcare service restrictions, such as through where possible
limiting hospital attendance in line with the RADS (Remote, Avoid,
Defer, Shorten) principle.8,9 The 18-member panel, which included
surgeons, clinical (radiation) oncologists and medical oncologists,
are listed in Supplementary information. Additional feedback was
received from patient and public representatives via Pancreatic
Cancer UK, a registered pancreatic cancer charity.
The proposals developed through this process are summarised
in Table 1 and have been revised as the COVID-19 outbreak has
evolved. They should serve to guide clinicians both as the initial
COVID-19 peak plateaus and resolves, and in any subsequent
disease outbreaks. These should be considered in conjunction
with other documents outlining stratification and prioritisation of
surgery, chemotherapy and radiotherapy (RT) delivery during the
COVID-19 pandemic.10–15
DIAGNOSIS OF PANCREATIC CANCER
With a number of other stakeholders, the British Society of
Gastroenterology has published guidance categorising upper
gastrointestinal endoscopy as an aerosol-generating procedure
and recommending that all elective and non-essential endoscopic
procedures should stop.16 It is recommended that endoscopic
therapy should continue for malignant biliary obstruction,
providing an opportunity to retrieve cytology from biliary
strictures or in the case of peri-ampullary neoplasm biopsy
specimens for some patients prior to self-expanding metal stent
insertion. In contrast, 2-week wait cancer referrals and cancer
staging endoscopic ultrasound are to be discussed on a case-by-
case basis. In instances where histology or cytology cannot be
obtained, the multidisciplinary team (MDT) should reach a
treatment recommendation based on balancing the risks of
inappropriately treating an alternative pathology, such as chronic
or autoimmune pancreatitis, against a watch-and-wait approach.
Options include proceeding to definitive treatment based on
imaging and elevated tumour markers where there is strong
suspicion of malignancy or offering treatment where repeat
investigations provide evidence for disease progression. Where
there is diagnostic uncertainty, patients must be counselled
regarding the possibility that they might not have cancer, but
would be at risk of developing life-threatening treatment
complications, or that in the absence of knowledge of the
histological cancer subtype, their treatment might be suboptimal.
Percutaneous biopsy may be feasible for more advanced disease,
while percutaneous fine-needle aspiration may also have to be
considered for localised disease if supported by radiology and
pathology expertise.
TREATMENT BY DISEASE STAGE
General principles
There is emerging but relatively low-level evidence that COVID-19
confers additional risk for patients with cancer, although this is not
as yet robustly quantified.7 Strategies to manage pancreatic
cancer should balance this risk and the impact of healthcare
resource limitations against the potential benefits of treatment;
Table 1. Suggested approaches for and key points relating to the management of patients with pancreatic cancer during the COVID-19 pandemic.
General principles
• The risks conferred by COVID-19 are greater for older patients and those with comorbidities.
• Minimise hospital visits, including through use of telephone consultations.
• Educate patients regarding the importance of physical distancing measures.
• Use hypofractionated regimes where radiotherapy is to be delivered.
• Dose modification and the use of prophylactic growth factor and antibiotics may mitigate SACT risks.
• Treatment decisions should be individualised, taking into account patient choice, followed by counselling of its risks and benefits.
Resectable and borderline resectable disease
Upfront treatment options
• Options for upfront resection are likely to be limited due to a lack of capacity and resources.
• Where surgery is unavailable, consider upfront SACT or hypofractionated precision RT/CRT.
• Where SACT can be used, FOLFIRINOX is preferred and may allow deferral of resection.
• For RT, consider 25–35 Gy/5# RT alone or 36–45 Gy/15# CRT with concurrent capecitabine.
Adjuvant SACT
• Without adjuvant SACT, survival following resection is <10%.
• Decisions to give adjuvant treatment are likely to be nuanced and based on a risk–benefit analysis.
• Treatment may be deferred by up to 12 weeks following surgery.
• The increased effectiveness of combination SACT should be weighed against the increased complications risk.
Locally advanced pancreatic cancer
• For fit patients without significant comorbidities, consider four cycles of modified FOLFORINOX ± consolidation hypofractionated RT/CRT.
• The risks of treatment in those aged over 80 years are likely to outweigh any benefit.
• For all other patients, consider upfront hypofractionated RT/CRT, with the aim of deferring SACT.
Metastatic disease
First-line treatment
• Risks of treatment are likely to outweigh benefits for most patients.
• Decisions to treat should be individualised and highly selective.
• SACT options include gemcitabine, gemcitabine plus nab-paclitaxel or FOLFIRINOX.
• Consider early response assessment and limiting duration of SACT where possible.
Second-line treatment
• Risks of treatment outweigh potential benefits and treatment should not be routinely offered to patients.
# fractions, COVID-19 coronavirus disease 2019, CRT chemoradiotherapy, FOLFIRINOX 5-fluorouracil, folinic acid, irinotecan and oxaliplatin, RT radiotherapy, SACT
systemic anticancer therapy.
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not least given that significant delays in therapy would ordinarily
be precluded by disease biology.17,18 Selected approaches will
need to adapt to emerging evidence related to COVID-19 and to
changes in the availability of key resources. Based on guidance
and priority setting from NHS England and the National Institute
for Health and Clinical Excellence, systemic anticancer therapy for
patients with resectable disease (priority levels 2–4) should be
ranked over locally advanced pancreatic cancer (LAPC; priority
levels 4 and 5) and metastatic disease (priority levels 4–6), should
prioritisation be required (see Supplementary Table 1).9,11 A
balanced discussion with patients is required to contextualise the
known and potential risks of COVID-19 against both the risks of
complications from the cancer itself and the potential for
complications from anticancer therapy and potential resource
limitations. In particular, it must be highlighted that our current
ability to mitigate and manage complications associated with
pancreatic surgery is predicated on an unlimited access to
multidisciplinary services, including physiotherapy, dietetics, nur-
sing, interventional radiology and intensive care.
Where SACT is administered, pragmatic options to mitigate risk
include dose modification and the use of prophylactic growth
factors and antibiotics. It is also important that all patients adhere
to the principles of physical distancing and that they are
supported to do so, such as through the use of telephone
consultations and remote assessments. In addition, clinical trials
and technical development initiatives (robotic surgery) should be
stopped in order to minimise resource burden.
In the event of varying regional pressures, particularly during
any second peaks of COVID-19, it may be beneficial to refer
patients for management in other regions. Where possible, this
option should be pursued and facilitated in order to ensure that
regional resource limitations do not hinder the provision of
optimal care.
Resectable and borderline resectable disease
Options for upfront resection are likely to be severely limited at
the initial height of the COVID-19 pandemic or in the event of
recurrent peaks in incidence. Consolidation of surgery in ‘ring-
fenced’ clean sites has helped to support some surgical capacity
during the first COVID-19 peak, although these centres have
limited capacity and are likely to be highly selective. Surgery
for resectable pancreatic cancer remains the optimal standard
of care, and where available should be pursued. Cancer
presentation, patient comorbidity, disease severity, regional
pandemic burden and regional hospital resources should be
considered when selecting patients for surgery. These decisions
are likely to remain dynamic and should draw on recommenda-
tions from SAGES-AHPBA (Society of American Gastrointestinal
and Endoscopic Surgeons-American Hepato-Pancreato-Biliary
Association).19
Where surgery is unlikely to be available due to a lack of
capacity or resources, consider upfront chemotherapy and/or
chemoradiotherapy (CRT). Treatment options include SACT
(evidence level 2a) and hypofractionated precision RT/CRT, as
outlined below, following an informed consent process.20 For RT
consider a dose of 25–35 Gy/5 fractions (RT alone, dose depending
on centre expertise) (evidence level 4) or 36 Gy/15 fractions CRT
with concurrent capecitabine (evidence level 1b).21,22 For SACT, a
combination of 5-fluorouracil, folinic acid, irinotecan and oxalipla-
tin (FOLFIRINOX) is preferred as the reported median progression-
free interval of 15 months could allow deferral of resection in
selected patients.23 While the magnitude of the additional
increase risk conferred by COVID-19 to patients with cancer,
particularly those undergoing chemotherapy, is unclear, the risk of
death is significantly greater in those with comorbidities and
those over 70 years of age.24,25 As such, FOLFIRINOX may be most
appropriate in patients with a good performance status without
significant comorbidities.
Decisions relating to the administration of adjuvant chemother-
apy should take into account patient choice, followed by
counselling of its risks and benefits. In the absence of adjuvant
chemotherapy, 5-year survival for patients who have undergone
resection is <10%, compared with over 20% for those who receive
adjuvant treatment.26–29 For example, in a recent randomised
controlled trial, adjuvant FOLFIRINOX delivered 3-year disease-free
survival of 39.7% and median overall survival of 54.4 months.26
Treatment could also be deferred for up to 12 weeks from surgery
(evidence level 1b).30 As with neoadjuvant SACT, decision on
appropriateness and choice of regimen should be guided by age,
comorbidity and potential magnitude of benefit. Nodal status
should also be considered given evidence that the outcomes of
patients without nodal metastases is more favourable.28 The
increased effectiveness of combination chemotherapy needs to
be balanced with the increased risks of complications, including
those relating to COVID-19.
Locally advanced pancreatic cancer
Patients with LAPC are conventionally managed with upfront
chemotherapy, with or without consolidation CRT. The use of
upfront hypofractionated (5 fractions, evidence level 2a) or,
alternatively, 15 fractions CRT (evidence level 4) may provide
lower-risk alternatives and may allow delaying the initiation of or a
break in SACT (evidence level 2a).31 This approach should,
however, be weighed against the risk of early metastatic
progression without upfront chemotherapy.30 Given the increas-
ing risks of COVID-19 with age, the risks of treatment in those
aged over 80 years are likely to outweigh any benefit and no
intervention is likely to be the best option for the majority of
patients. For fit patients without significant comorbidities,
consider four cycles of modified FOLFIRINOX with or without
consolidation hypofractionated CRT or five fraction RT alone23,32
(evidence level 2a).
Metastatic disease
The risks of treatment for metastatic disease are likely to outweigh
the benefits in many patients as the median improvement in
survival is usually <6 months. A decision to initiate palliative
chemotherapy should be individualised and highly selective;
options for consideration include single-agent gemcitabine,
gemcitabine plus nab-paclitaxel and FOLFIRINOX in order of
increasing efficacy and increasing toxicity (evidence level 1b).33,34
In order to mitigate risks, clinicians should consider early response
assessment (if radiology capacity allows) to limit duration of
chemotherapy. A break from chemotherapy may be considered in
patients with low volume disease or those with good disease
control (evidence level 5). The limited benefits of second-line
chemotherapy outweigh the potential benefits and should not be
routinely offered to patients (evidence level 5).
HYPOFRACTIONATED RADIATION APPROACHES
Frequent hospital visits will increase risk of patients contracting
COVID-19, therefore conventional CRT (25–30 fractions) should be
avoided. Hypofractionated RT (5–15 fractions) reduces footfall, is
less immunosuppressive than chemotherapy and the total overall
time in hospital is likely to be less than or comparable to patients
receiving 3 months of FOLFIRINOX-or gemcitabine-based che-
motherapy. Detailed RT delivery guidance document and evi-
dence for their use is available at www.uppergicancer.com. A
summary of key points is provided in Table 2.
RT alone
Dose fractionation: 30 Gy/5 fractions (range 25–35 Gy/5 fractions,
daily or alternate day fractionation). Oncologists who have
experience of delivering upper abdominal/pancreatic stereotactic
ablative radiotherapy (SABR) could deliver radiation at higher
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doses of 33–35 Gy/5 fractions using SABR. For those without this
expertise, a lower dose of 30 Gy/5 fraction should be considered.
Simultaneous integrated boost to tumour/vessel contact (40 Gy)
may be considered.35
Chemoradiotherapy
Dose fractionation: 36 Gy/15 (preoperative CRT) or 45 Gy/15 fractions
(definitive CRT) with capecitabine (830mg/m2 b.d. on days of
RT). This regime should be deliverable by all units with experience
in pancreatic RT, the final doses being driven by the normal tissue
constraints. A dose of 45–50 Gy/15 fractions is radiobiologically
equivalent to conventionally fractionated regimes used in the UK.
While the α/β value for pancreatic adenocarcinoma has not been
fully elucidated, it is likely to range between 4 and 10, giving an
EQD2 (equivalent dose) of 52.5–61.6 Gy, assuming an α/β of 4, or of
48.8–55.6 Gy, assuming an α/β of 10.36,37
SUMMARY
The COVID-19 pandemic poses an unprecedented challenge to the
management of patients with cancer; both through a heightened
risk of life-threatening infection and through pressure on health
services. We have outlined here, based on the best available
evidence and UK expert consensus, suggestions for optimising the
outcomes of patients with pancreatic cancer. It is vital that decisions
are individualised for patients following MDT discussion, and that
patients are comprehensively counselled regarding treatment
options prior to providing informed consent. Equally, it will be
important to evaluate the management options outlined here and
clinicians are encouraged to visit www.uppergicancer.com to
participate in prospective data collection. Finally, while there is a
need to accommodate for the enhanced risks and impact on
services from COVID-19, this must not result in a return to the
nihilism that has dogged pancreatic cancer for many decades. In
these challenging times, compassion and empathy remain key
during what is already a frightening period for our patients.
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